Literature DB >> 26205399

Clinical trials in melanoma patients with brain metastases.

Melinda L Yushak1, Veronica L Chiang2, Harriet M Kluger1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26205399      PMCID： PMC4834841          DOI： 10.1111/pcmr.12401

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  13 in total

1.  Brain metastases from HER2-positive breast cancer - authors' reply.

Authors:  Thomas Bachelot; Claire Cropet; Véronique Diéras; Marta Jimenez; Mario Campone
Journal:  Lancet Oncol       Date:  2013-01       Impact factor: 41.316

2.  Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.

Authors:  Jeffrey S Weber; Asim Amin; David Minor; Jonathan Siegel; David Berman; Steven J O'Day
Journal:  Melanoma Res       Date:  2011-12       Impact factor: 3.599

3.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

Authors:  Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascierto; Paul B Chapman; Igor Puzanov; Axel Hauschild; Caroline Robert; Alain Algazi; Laurent Mortier; Hussein Tawbi; Tabea Wilhelm; Lisa Zimmer; Julie Switzky; Suzanne Swann; Anne-Marie Martin; Mary Guckert; Vicki Goodman; Michael Streit; John M Kirkwood; Dirk Schadendorf
Journal:  Lancet Oncol       Date:  2012-10-08       Impact factor: 41.316

4.  Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases.

Authors:  Ravi K Amaravadi; Lynn M Schuchter; David F McDermott; Amy Kramer; Lydia Giles; Kristi Gramlich; Mary Carberry; Andrea B Troxel; Richard Letrero; Katherine L Nathanson; Michael B Atkins; Peter J O'Dwyer; Keith T Flaherty
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

5.  Melanoma brain metastases: is it time to reassess the bias?

Authors:  Jaclyn C Flanigan; Lucia B Jilaveanu; Mark Faries; Mario Sznol; Stephan Ariyan; James B Yu; Jonathan P S Knisely; Veronica L Chiang; Harriet M Kluger
Journal:  Curr Probl Cancer       Date:  2011 Jul-Aug       Impact factor: 3.187

6.  Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

Authors:  Anna Maria Di Giacomo; Paolo A Ascierto; Lorenzo Pilla; Mario Santinami; Pier Francesco Ferrucci; Diana Giannarelli; Antonella Marasco; Licia Rivoltini; Ester Simeone; Stefania Vl Nicoletti; Ester Fonsatti; Diego Annesi; Paola Queirolo; Alessandro Testori; Ruggero Ridolfi; Giorgio Parmiani; Michele Maio
Journal:  Lancet Oncol       Date:  2012-08-13       Impact factor: 41.316

7.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

Authors:  Kim Margolin; Marc S Ernstoff; Omid Hamid; Donald Lawrence; David McDermott; Igor Puzanov; Jedd D Wolchok; Joseph I Clark; Mario Sznol; Theodore F Logan; Jon Richards; Tracy Michener; Agnes Balogh; Kevin N Heller; F Stephen Hodi
Journal:  Lancet Oncol       Date:  2012-03-27       Impact factor: 41.316

8.  Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.

Authors:  Reinhard Dummer; Simone M Goldinger; Christian P Turtschi; Nina B Eggmann; Olivier Michielin; Lada Mitchell; Luisa Veronese; Paul René Hilfiker; Lea Felderer; Jeannine D Rinderknecht
Journal:  Eur J Cancer       Date:  2013-11-29       Impact factor: 9.162

Review 9.  Advances in therapy for melanoma brain metastases.

Authors:  Jaclyn C Flanigan; Lucia B Jilaveanu; Veronica L Chiang; Harriet M Kluger
Journal:  Clin Dermatol       Date:  2013 May-Jun       Impact factor: 3.541

10.  Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.

Authors:  Geoffrey T Gibney; Geneviève Gauthier; Charles Ayas; Philip Galebach; Eric Q Wu; Sarang Abhyankar; Carolina Reyes; Annie Guérin; Yeun Mi Yim
Journal:  Cancer Med       Date:  2015-05-20       Impact factor: 4.452
View more
  5 in total

1.  Comparing available criteria for measuring brain metastasis response to immunotherapy.

Authors:  Jack M Qian; Amit Mahajan; James B Yu; A John Tsiouris; Sarah B Goldberg; Harriet M Kluger; Veronica L S Chiang
Journal:  J Neurooncol       Date:  2017-03-08       Impact factor: 4.130

Review 2.  Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.

Authors:  Grainne M O'Kane; Catherine Labbé; Mark K Doherty; Kelvin Young; Hamzeh Albaba; Natasha B Leighl
Journal:  Oncologist       Date:  2016-08-17

3.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

Review 4.  Systemic Immunotherapy for the Treatment of Brain Metastases.

Authors:  Justine V Cohen; Harriet M Kluger
Journal:  Front Oncol       Date:  2016-03-09       Impact factor: 6.244

5.  Outcomes of Treatment for Melanoma Brain Metastases.

Authors:  Mantas Janavicius; Nadezda Lachej; Giedre Anglickiene; Ieva Vincerzevskiene; Birute Brasiuniene
Journal:  J Skin Cancer       Date:  2020-11-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.